Institute of Medicine
Committee on a Review of the California Institute for Regenerative Medicine
Arnold and Mabel Beckman Center
of the National Academies of Sciences and Engineering
Irvine, CA 92617
April 10, 2012
The meeting audiocast will be linked from the National Academy of Science's home page:www.nationalacademies.org
9:00 a.m. WELCOME AND COMMITTEE INTRODUCTIONS
Harold T. Shapiro, Ph.D.
IOM Committee Chair
9:10 a.m. OVERVIEW OF LITTLE HOOVER COMMISSION REPORT
Stuart Drown (by phone)
Little Hoover Commission
10:00 a.m. PERSPECTIVES ON CIRM FROM STAKEHOLDERS
California Deputy State Controller
Ken Taymor, J.D. (by phone)
Berkeley Center for Law, Business and Economy
John Simpson (by phone)
Director, Stem Cell Oversight and Accountability Project
Marcy Darnovsky, PhD (by phone)
Associate Executive Director Center for Genetics and Society
California Stem Cell Report
11:30 a.m. LUNCH
12:00 p.m. PERSPECTIVES FROM CIRM APPLICANTS
Leonard H. Rome, Ph.D. (by phone) Senior Associate Dean for Research Professor of Biological Chemistry David Geffen School of Medicine at UCLA
Xuejun H. Parsons, Ph.D. Associate Professor of Regenerative Medicine, Scientific Director in Cardiovascular and Neural Regeneration, San Diego Regenerative Medicine Institute
12:45 p.m. PERSPECTIVES ON CIRM FROM DISEASE TEAM INVESTIGATORS
Donald Kohn, M.D.
Professor, Department of Microbiology, Immunology, and Molecular Genetics and Department of Pediatrics, University of California, Los Angeles
Larry Goldstein, Ph.D. Professor
Department of Cellular and Molecular Medicine Department of Neurosciences UC San Diego School of Medicine
Dennis Clegg, Ph.D.
Professor, Molecular, Cellular, and Developmental Biology University of Southern California
Catriona Jamieson, M.D., Ph.D.
Associate Professor, Division of Hematology-Oncology UC San Diego Moores Cancer Center
2:00 p.m. PERSPECTIVES ON CIRM FROM INDUSTRY
Gregory A. Bonfiglio, J.D., Panel Moderator
Managing Partner, Proteus Venture Partners
Michael D. West, Ph.D.
Chief Executive Officer, BioTime, Inc.
Allan Robins, Ph.D.
Acting Chief Executive Officer, Vice President and Chief Technical Officer, ViaCyte, Inc.
Gail K. Naughton, Ph.D.
CEO, Chairman of the Board, Histogen, Inc.
3:30 p.m. BREAK
3:45 p.m. PERSPECTIVES ON CIRM FROM TECHNOLOGY TRANSFER OFFICERS
Casie Kelly, Ph.D. Technology Transfer Officer, Life Sciences
Office of Intellectual Property & Industry Sponsored Research, University of California, Los Angeles
4:30 p.m. PUBLIC COMMENT
Individuals register for a slot and have 5 minutes for comments on any topic related to the study charge.
5:30 p.m. ADJOURN OPEN SESSION